Abstract
From 2010 to 2012, nine systematic reviews reported highly variable conclusions regarding the association between carriage of a cytochrome P450 2C19 loss-of-function allele and the risk of adverse cardiovascular (CV) events in individuals using clopidogrel. Possible contributors to the variable findings include differences in patient populations, CV end points, and statistical models utilized by the systematic reviews, as well as unexplained heterogeneity, inconsistent/incomplete reporting, and risk of publication bias with respect to the primary studies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aryl Hydrocarbon Hydroxylases / genetics*
-
Cardiovascular Diseases / chemically induced
-
Clinical Trials as Topic / standards
-
Clopidogrel
-
Cytochrome P-450 CYP2C19
-
Endpoint Determination
-
Genotype
-
Humans
-
Meta-Analysis as Topic*
-
Models, Statistical
-
Patient Selection
-
Platelet Aggregation Inhibitors / adverse effects*
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Publication Bias
-
Research Design / standards
-
Review Literature as Topic*
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / pharmacokinetics
Substances
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Aryl Hydrocarbon Hydroxylases
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Ticlopidine